The nucleus is a key organelle in mammary cells, which is responsible for several cellular functions including cell proliferation, gene expression, and cell survival. In addition, the nucleus is the primary targets of doxorubicin treatment. In the current study, low-abundance nuclear proteins were enriched for proteomic analysis by using a state-of-the-art two-dimensional differential gel electrophoresis (2D-DIGE) and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) strategy to compare and identify the nuclear protein profiling changes responsible for the development of doxorubicin resistance in human uterine cancer cells. The results of the nuclear proteomic analysis indicated that more than 2100 protein features were resolved from an equal pooled amount of three purified nuclear proteins and 117 differentially expressed spots were identified. Of these 117 identified proteins, 48 belonged to nuclear proteins and a positive correlation was observed between the expression levels of 32 of these nuclear proteins and an increase in drug resistance. According to our review of relevant research, nuclear proteins such as DNA repair protein XRCC3 (XRCC3) have not been reported to play roles in the formation of doxorubicin resistance. Previous studies have used RNA interference and cell viability analysis to evidence the essential roles of XRCC3 on its potency in the formation of doxorubicin resistance. To sum up, our nuclear proteomic approaches enabled us to identify numerous proteins, including XRCC3, involved in various drug-resistance-forming mechanisms. Our results provide potential diagnostic markers and therapeutic candidates for treating doxorubicin-resistant uterine cancer.
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Doxorubicin is an anticancer drug widely used in treating a wide range of tumor types (Green and Rose, 2006; Vatsyayan et al., 2009; Verma et al., 2008) . The action mechanism of doxorubicin is complex. A previous study indicated that doxorubicin disturbs DNA replication by becoming intercalated into DNA molecules, thus inhibiting DNA, RNA, and protein synthesis. Moreover, doxorubicin has been reported to interact with topoisomerase 2 and lead to the breakage of DNA double strands, preventing DNA synthesis. In addition, doxorubicin directly impairs cancer cells by disturbing the normal physiology of the nucleus resulting in cell apoptosis (Tsuruo et al., 2003; Turner and Sullivan, 2008) . However, doxorubicininduced chemotherapy resistance has been widely reported in cancers such as leukemia, osteosarcoma, breast cancer, lung cancer, and uterine cancer (Biing et al., 1994; Ferreira et al., 2006; Harisi et al., 2007; Hui et al., 2008; Song et al., 2006) , and is a major therapeutic problem preventing the successful treatment of patients receiving cancer chemotherapy.
Chemotherapy resistance reduces the usefulness of anticancer drugs used in the treatment of tumors. In clinical practice, chemotherapy resistance has been recognized as a severe problem when the concentrations of chemotherapy drugs reach toxic and harmful doses killing both normal cells and cancer cells. Previous studies have reported biological mechanisms associated with drug resistance, including the enhanced activity of membrane-embedded drug efflux transporters such as adenosine-triphosphate-binding cassette transporters, increased levels of intracellular detoxification enzymes such as glutathione reductase, and the regulation of cellular signal transduction pathways that control cell survival and cell death (Lage, 2008) . However, chemotherapy resistance cannot be explained entirely by these mechanisms. Consequently, comprehensively investigating additional resistance mechanisms that have not yet been elucidated are crucial.
Because the development of chemotherapy resistance involves multiple factors and is linked to alterations in many proteins, proteomic strategies were used to discover chemotherapyresistance-related proteins. In our previous proteomic analysis, we identified numerous proteins, including asparagine synthetase and membrane-associated progesterone receptor component 1, involved in various drug-resistance-forming mechanisms . In this study, to reduce complexity and detect low-abundance proteins, subcellular proteomic anal-NUCLEAR PROTEOMIC ANALYSIS OF DOXORUBICIN RESISTANCE ASSOCIATED PROTEINS 397 ysis based on the purification of nuclear proteins was performed to study the relationship between the nucleus and doxorubicininduced drug resistance because the nucleus is essential for the survival of resistant cancer cells and defects in the nucleus contribute to the development of chemotherapy resistance. To conduct an in vitro investigation of doxorubicin resistance mechanisms in uterine cancer, increase our understanding of the doxorubicin related molecular processes, and identify potential low-abundance resistance biomarkers with possible diagnostic or therapeutic applications, we established a pair of uterine sarcoma cancer lines, MES-SA, and doxorubicin-resistant partners, MES-SA/Dx-2M cells and MES-SA/Dx-8M cells, as a model system for examining resistance-dependent nuclear protein alterations by conducting quantitative proteomic analysis using two-dimensional differential gel electrophoresis (2D-DIGE) and matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry. In addition, this paper reviews studies that used RNA interference against a selected identified protein, DNA repair protein XRCC3 (XRCC3), to monitor, and evaluate its potency against doxorubicin chemotherapy resistance.
MATERIALS AND METHODS

Chemical and Reagents
Generic chemicals were purchased from Sigma-Aldrich (St Louis), whereas reagents for 2D-DIGE were purchased from GE Healthcare (Uppsala, Sweden). All primary antibodies were purchased from Genetex (Hsinchu, Taiwan) and antimouse and antirabbit secondary antibodies were purchased from GE Healthcare (Uppsala, Sweden). All the chemicals and biochemicals used in this study were of analytical grade.
Cell lines and cell cultures. The uterine sarcoma cancer line, MES-SA was purchased from American Type Culture Collection (Manassas, VA) and cultured in McCoy's 5a modified medium containing 10% fetal bovine serum (FBS), l-glutamine (2mM), streptomycin (100 g/ml), and penicillin (100 IU/ml) (all from Gibco-Invitrogen Corp., Paisley, UK). The doxorubicin resistance lines, MES-SA/Dx-2M and MES-SA/Dx-8M cells, were both derived from MES-SA via stepwise increasing the doxorubicin concentrations in medium and were cultured in the same medium and supplement with 0.2 and 0.8M doxorubicin, respectively. All cells were incubated at 37
• C in a humidified atmosphere containing 5% CO 2 .
Sample preparation for nuclear proteomic analysis. For nuclear protein isolation, MES-SA, MES-SA/Dx-2M and MES-SA/Dx-8M cells were washed in chilled 0.5× PBS and then scraped into homogenization buffer containing 20mM HEPES, pH 7.9, 10mM KCl, 1mM EDTA, 10% glycerol, 0.2% NP-40 containing protease inhibitors. Cells were then lysed with Dounce homogenization and fractionated with centrifugation at 12,000 × g for 1 min at 4
• C. The resulting pellet was resuspended with buffer containing 20mM HEPES, pH 7.9, 0.42M NaCl, 0.2mM EDTA, 1.5mM MgCl 2 , 25% glycerol, and protease inhibitor cocktail, and incubated with agitation for 30 min at 4
• C before centrifugation for 10 min at 12,000 × g. The resulting supernatants were collected and used for nuclear proteomic analysis and nuclear protein concentrations were determined using the coomassie protein assay reagent (Bio-Rad).
MTT cell viability assay. The detailed 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) experimental procedure has been described in our previous study . -DIGE, gel image analysis, protein staining, in-gel digestion, and MALDI-TOF MS analysis . The detailed experimental procedures have been described in our previous study Lai et al., 2010; Wu et al., 2012) . For 2D-DIGE analysis, protein samples were labeled with N-hydroxy succinimidyl ester-derivatives of the cyanine dyes Cy2, Cy3, and Cy5. Briefly, 100 g of protein sample in triplicate was minimally labeled with 250 pmol of either Cy3 or Cy5 for comparison on the same 2-DE gel. To facilitate image matching and cross-gel statistical comparison, a pool of all samples was also prepared and labeled with Cy2 at a molar ratio of 2.5 pmol Cy2/g of protein as an internal standard run on all gels. The labeling reactions were performed for 30 min on ice in the dark and then quenched with a 20-fold molar excess of free l-lysine to dye for 10 min. The differentially Cy3-and Cy5-labeled samples were then mixed with the Cy2-labeled internal standard and reduced with dithiothreitol for 10 min. Immobilized nonlinear pH gradient (IPG) buffer, pH 3-10 nonlinear (2% (vol/vol), GE Healthcare) was added and the final volume adjusted to 450 l with 2D-lysis buffer for overnight rehydration into IPG strips (pH 3-10, 24 cm). Isoelectric focusing was then performed using a Multiphor II apparatus (GE Healthcare) for a total of 62.5 kVh at 20 • C. Strips were then equilibrated in 6M urea, 30% (vol/vol) glycerol, 1% SDS (wt/vol), 100mM Tris-HCl (pH 8.8) with 65mM dithiothreitol for 15 min and then in the same buffer containing 240mM iodoacetamide for a further 15 min. Equilibrated IPG strips were transferred onto 24 cm × 20 cm 12.5% polyacrylamide gels cast between low-fluorescence glass plates and bonded to one of the plates. The strips were overlaid with 0.5% (wt/vol) low melting point agarose in running buffer containing bromophenol blue. The gels were run in an Ettan Twelve gel tank (GE Healthcare) at 4 W per gel at 10
2D
• C until the dye front had completely run off the bottom of the gels. Gels were then scanned directly between the glass plates using an Ettan DIGE Imager (GE Healthcare) according to the manufacturer's instructions. Image analysis was performed using DeCyder 2-D Differential Analysis Software v7.0 (GE Healthcare) to codetect, normalize, and quantify the protein features in the images. Features detected from nonprotein sources were filtered out. Spots displaying a ≥1.5 average-fold increase or decrease 398 CHANG ET AL.
in abundance with a p-value <0.05 were selected for protein identification.
For mass spectrometry analysis, peaks in the mass range of m/z 800-3000 were used to generate a peptide mass fingerprint that was searched against the Swiss-Prot/TrEMBL database (v57.12) with 513,877 entries using Mascot software v2.2.06 (Matrix Science, London, UK). The following parameters were used for the search: Homo sapiens; tryptic digest with a maximum of one missed cleavage; carbamidomethylation of cysteine, partial protein N-terminal acetylation, partial methionine oxidation, and partial modification of glutamine to pyroglutamate and a mass tolerance of 50 ppm. Identification was accepted based on significant MASCOT MOWSE scores (p < 0.05), spectrum annotation and observed versus expected molecular weight and pI on 2-DE as well as at least five peptides in each identified protein.
Immunoblotting analysis. Immunoblotting analysis was used to validate the differential abundance of mass spectrometry identified proteins across MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M cells. The detailed experimental procedure has been described in our previous study (Hung et al., 2011) . All primary antibodies used for expression validation were purchased from Genetex (Hsinchu, Taiwan).
siRNA design, construction, and transfection. The siRNA against XRCC3 was synthesized by Invitrogen. The targeting sequences 5 -CCA GAA UUA UUG CUG CAA UUA AGA A-3 against XRCC3 were designed and verified to be specific by Blast search against the human genome, and sequences of similar GC contents which do not match any known human coding sequence were used for negative control against XRCC3. Transfection was mediated with Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instruction. Briefly, cells were transfected with 100nM of XRCC3 siRNA or the corresponding control (pGCsi-control) in serum-free medium containing Lipofectamine RNAiMAX for 4 h followed by recovered in medium containing 10% Fetal Calf Serum (FCS) for 24 h. The efficiency of siRNA knockdown was monitored with immunoblotting by using primary antibodies against XRCC3.
RESULTS
Development of doxorubicin resistance uterine cancer lines.
For this study, we prepared a doxorubicin-sensitive uterine cancer cell line, MES-SA, by growing in a doxorubicin-free medium containing 10% (vol/vol) FBS. The MES-SA-resistant cell lines, MES-SA/Dx-2M and MES-SA/Dx-8M, were maintained under continuous exposure to 0.2 and 0.8M doxorubicin, respectively, to keep the doxorubicin resistance phenotype, and the doxorubicin-resistant lines were cultured in a drug-free medium for 1 week prior to perform experiments in this study. The IC 50 of MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M cells were 0.14, 4.08, and 18.12M, respectively (Fig. 1A) . MES-SA/Dx-2M and MES-SA/Dx-8M cells showed an upregulation in P-glycoprotein levels (Fig. 1B) , demonstrating a significant difference in doxorubicin resistance across MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M cells. These distinctly different physiological and biochemical characteristics made these cell lines suitable for chemotherapyresistant cell model for a doxorubicin-resistance-associated research.
2D-DIGE and MALDI-TOF MS analysis of the nuclear proteomes across MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M cells.
For nuclear proteome analysis, MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M were grown on cell culture dishes and the confluency of cells was checked prior to perform nuclear protein extraction. To examine the efficiency of nuclear protein extraction, immunoblotting analysis of the HDAC1 (nuclear marker) and ␤-actin (cytosolic marker) lev-
FIG. 2.
Analysis of purity of the nuclear protein extracts by immunoblotting analysis. Nuclear fractions were prepared from MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M cells. Purity of nuclear fractions was determined by immunoblotting analysis using antibodies against cytoplasmic localized marker protein: ␣-actin and a nucleus localized marker protein: HDAC1. els were carried out and the results showed the nuclear fractions were significantly enriched (Fig. 2) . The 2D-DIGE analysis shows that there is a significant protein expression profiling changes between the nuclear fraction and cytosolic fraction indicating the established nuclear enrichment is appropriate for providing downstream nuclear proteome analysis (data not shown).
To identify altered abundance of nuclear proteins and relate it to the formation of chemotherapy-resistance-induced by doxorubicin, the nuclear proteomic profiles of MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M were analyzed. The three replicates of the three different nuclear fractions were compared by 2D-DIGE to have a global overview of uterine cell doxorubicin resistance (Fig. 3A) . After image analysis with DeCyder v7.0, 2161 protein spots were well-defined (Fig. 3B) . In order to reduce the intrinsic variability caused by protein sample and gel-to-gel variation, only those protein features appeared at least in all of the triplicate gel images were selected for statistical analysis. Furthermore, biological variation analysis of spots showing greater than 1.5-fold change in expression with a t-test score of <0.05 were visually checked before confirming the alterations for protein identification. MALDI-TOF MS identification revealed 117 unique differentially expressed proteins across MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M. In which, 48 (41%) identified proteins were dominantly nucleus-located proteins (Fig. 4A ). Of the 48 nuclear proteins, 32 of these proteins were shown doxorubicin dose-dependent changes across MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M (Fig. 4A and Table 1 ). In these nuclear proteins, most of them were involved in gene expression, protein folding and redox-regulation (Fig. 4B) . Importantly, numerous identified spots such as PARK7 and XRCC3 have not been reported in drug-resistance-associated study in our knowledge means these proteins are putative nuclear regulatory proteins in response to the formation of drug resistance. As expect, some of well known resistance markers such as nucleoside diphosphate kinase A were also identified in this proteomic experiment (Okabe-Kado et al., 1992) .
FIG. 3.
Analysis of the uterine nuclear proteomes of MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M cells by 2D-DIGE. Nuclear proteins (100 g each) purified from MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M cells were labeled with Cy-dyes and separated using 24 cm, pH 3-10 nonlinear IPG strips followed by resolved with 12.5% SDS-PAGE. (A) Samples arrangement for a triplicate 2D-DIGE experiment. (B) The dose-dependent differentially expressed nuclear protein features are annotated with circles.
Validation of characterized resistance-associated nuclear proteins via immunoblotting. The proteomic study identified numerous doxorubicin resistance-associated nuclear proteins. It was essential to validate the expression of these proteins using independent biochemical experiments. To this end, we used immunoblotting analyses to confirm the expression levels of peptidyl-prolyl cis-trans isomerase FKBP4 (FKBP4), glutathione S-transferase P (GSTP1), heat shock protein beta-1 (HSP27), DNA repair protein XRCC3 (XRCC3), Parkinson disease 7 (PARK7), histone-binding protein RBBP4 (RBBP4), far upstream element-binding protein 1 (FUBP1), mitotic checkpoint protein BUB3 (BUB3), heterogeneous nuclear ribonucleoprotein D (hnRPD), far upstream element-binding protein 1 (FUBP1), and non-POU domain-containing octamer-binding protein (NONO) obtained from the nuclear fractions of MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M (Fig. 5) . The levels of identified nuclear proteins including FKBP4, GSTP1, HSP27, XRCC3, and PARK7 showed upregulated trends in the nuclear fractions of MES-SA/Dx-2M and MES-SA/Dx-8M, compared with the levels present in MES-SA in both 2D- 
FIG. 4. Percentage of intracellular locations of isolated nuclear fractions identified by 2D-DIGE/MALDI-TOF MS for MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M cells (A). Percentage of identified dose-dependent differentially expressed nuclear proteins according to their biological functions (B).
DIGE analysis and immunoblotting validation. In contrast, the levels of identified proteins including RBBP4, FUBP1, BUB3, hnRPD, FUBP1, and NONO showed downregulated trends in the nuclear fractions of MES-SA/Dx-2M and MES-SA/Dx-8M, compared with the levels present in MES-SA in both 2D-DIGE analysis and immunoblotting validation. This observation confirmed that these differentially expressed proteins are associated with doxorubicin-specific resistance in uterine cancer. Overall, our immunoblotting results are in agreement with the 2D-DIGE analysis results.
Evaluation of the role of XRCC3 in doxorubicin resistance in uterine cancer using siRNA knockdown. We observed that XRCC3 is overexpressed in doxorubicin-resistant MES-SA/Dx-2M and MES-SA/Dx-8M cells compared with doxorubicin-sensitive MES-SA cells; this protein is one of the differentially expressed proteins identified in our proteomic analysis. We subjected MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M cells to knockdown experiments to evaluate the role of XRCC3 in doxorubicin resistance. An immunoblot analysis revealed >70% efficiency in the reduction of endogenous XRCC3 levels when ␣-tubulin was used as the internal standard (Figs. 5 and 6A ). XRCC3 expression cannot FIG. 5. Representative immunoblotting analyses for selected differentially expressed nuclear proteins identified by proteomic analysis in MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M cells. The levels of identified proteins including FKBP4, GSTP1, HSP27, XRCC3, and PARK7 showed upregulated trends in both 2D-DIGE analysis and immunoblotting validation (upper panel). The levels of identified proteins including RBBP4, FUBP1, BUB3, hnRPD, FUBP1, and NONO showed downregulated trends in both 2D-DIGE analysis and immunoblotting validation (bottom panel). HDAC1 was used as an internal control in the validation.
be completely silenced because of the long half-life of XRCC3. Knocking down XRCC3 with the indicated concentrations of siRNA significantly reduced viability in the MES-SA/Dx-2M and MES-SA/Dx-8M cells by approximately 30 and 60%, respectively, at individual IC 50 concentrations (Fig. 6B ). An MTT assay revealed no significantly decreased viability in XRCC3-knockdown MES-SA cells treated with the indicated concentrations of doxorubicin compared with scrambled siRNA transfected controls (Fig. 6B) . The incomplete silencing of XRCC3 might prevent the cell viability of XRCC3 silencing cells from
FIG. 6.
Effect of doxorubicin on cell viability of XRCC3 siRNAsilenced MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M cells. (A) MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M cells grown overnight were pretreated with 100nM XRCC3-specific siRNA or scramble siRNA with similar GC content. Expression of XRCC3 in MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M cells were monitored by immunoblotting by using primary antibodies against XRCC3. (B) MTT-based viability assays were performed where 5000 MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M cells seeded into 96-well plate for overnight incubation followed by pretreated with 100nM XRCC3-specific siRNA combining with corresponding scramble siRNA. After 24 h, cells were treated with indicated concentrations of doxorubicin for 24 h followed by incubated with MTT and then dimethyl sulfoxide (DMSO) added and the plates shaken for 20 min followed by measurement of the absorbance at 540 nm. Values were normalized against the untreated samples and are the average of four independent measurements ± SD.
reaching the baseline level during doxorubicin treatment (Fig.  6B) .
We used flow cytometry with propidium iodide staining and annexin V- knockdown has no direct effect on doxorubicin-induced MES-SA cell apoptosis (Fig. 7A) . By contrast, doxorubicin treatment of MES-SA/Dx-2M cells from 0 × IC 50 to 0.5 × IC 50 increases the percentages of total apoptotic cells (LR + UR) from 8.1 to 9.7% compared with changes from 15.2 to 31.2% in XRCC3 knockdown MES-SA/Dx-2M cells. Notably, the numbers of late apoptotic cells (UR) in control MES-SA/Dx-2M and XRCC3 knockdown MES-SA/Dx-2M cells showed increases to 13.5-fold (from 6.1 to 6.7% and from 11.9 to 20%), respectively (Fig. 7B) . Additionally, doxorubicin treatment of MES-SA/Dx-8M cells from 0 × IC 50 to 0.5 × IC 50 increases the percentages of total apoptotic cells (LR + UR) from 8.0 to 11.8% compared with changes from 9.9 to 17.9% in XRCC3 knockdown MES-SA/Dx-8M cells (Fig. 7C) . These results indicated that XRCC3 knockdown has a significant role on doxorubicin-induced apoptosis in resistant cells, MES-SA/Dx-2M and MES-SA/Dx-8M, implying XRCC3 knockdown has an auxiliary effect to increase resistant cell death during doxorubicin treatment. In addition, the numbers of total apoptotic cells (LR + UR) in XRCC3 silenced MES-SA/Dx-2M and MES-SA/Dx-8M cells are greater than the numbers for parental MES-SA/Dx-2M and MES-SA/Dx-8M cells, implying that XRCC3 RNAi alone are sufficient to induce MES-SA/Dx-2M and MES-SA/Dx-8M cellular apoptosis.
DISCUSSION
A clear understanding of chemotherapy-associated drug resistance mechanisms is essential for offering opportunities in both drug resistance detection and therapy. The results of this study indicated that the nucleus is one of the primary targets for chemotherapeutic drugs. In addition, mutations within the nuclear genomes have been reported in numerous cancers and are believed to promote chemoresistance (Huang et al., 2011; Lewin et al., 2007) . Most of the functional mechanisms of chemoresistance have been delineated in transcription-based rather than translation-level studies. Thus, in the current study, we adopted a comprehensive nuclear proteomic approach based on 2D-DIGE analysis coupled with MALDI-TOF MS to identify nuclear proteins that were differentially expressed in the doxorubicin-resistant human uterine cancer cell lines MES-SA/Dx-2M and MES-SA/Dx-8M, and their parental cell line, MES-SA, and, thus, provides a comprehensive view of the protein expression and protein-protein interactions associated with doxorubicin resistance in uterine cancer. The identified proteins might serve as potential-resistant markers for the prognosis or diagnosis of uterine cancer, and patients can be treated with doxorubicin or other chemotherapy drugs, such as 5-fluorouracil, accordingly.
In our nuclear proteomic analysis, we identified 117 differentially expressed protein features from isolated nuclear fractions in MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M cells. Of the identified proteins, 32 were located in the nucleus, and the expression levels of these proteins were positively correlated with drug resistance. Although only 41% of the isolated proteins were located in the nucleus, the percentage was higher than that observed in a general total cellular protein analysis. Numerous cytosolic proteins are able to translocate into the nucleus, but are assigned to be cytosolic proteins, contributing to the low coverage rate of the nuclear fraction in total enriched proteins.
The results of this study indicated that XRCC3 is potentially involved in the formation of doxorubicin drug resistance. We confirmed the functions of XRCC3 in chemotherapy resistance, and observed that XRCC3 overexpression contributes significantly to the development of doxorubicin resistance in MES-SA/Dx-2M and MES-SA/Dx-8M cells. The results indicated that multiple mechanisms are associated with the development of drug resistance in uterine cancer cells, and that these mechanisms might contribute to chemotherapeutic resistance in the treatment of uterine cancer.
XRCC3 is a nuclear protein that participates in homologous recombination to repair DNA damage and maintain chromosome stability. XRCC3 is a protein that is encoded by the XRCC3 gene in human. This gene encodes a family of RecA/Rad51-related proteins to repair DNA damage involved in the homologous recombination repair of double-stranded DNA and repair of chromosomal fragmentation, translocation and deletion (Tebbs et al., 1995) . A previous study reported that XRCC3 assembles a repair protein complex with XRCC2, RAD51B, RAD51C, and RAD51D proteins (Xu et al., 2005) . A recent cancer study indicated that the overexpression of XRCC3 in MCF7 cells resulted in increased resistance to cisplatin/melphalan treatment and reduced cisplatininduced MCF7 apoptosis (Martinez-Marignac et al., 2011) . In addition, the overexpression of XRCC3 increased invasiveness in both MCF7 and BT20 in vitro. Moreover, XRCC3 overexpressed MCF7 exhibited a greater tumorigenesis when the activity of matrix metalloproteinase 9 and the expression of regulators of cell-cell adhesion and metastasis such as CD44 were increased (Martinez-Marignac et al., 2011) . Thus, XRCC3 plays vital roles in the modulation of DNA repair, resistance to cisplatin/melphalan treatment, enhancement of invasiveness, and tumorigenesis. However, according to our thorough review of relevant research, no report has described the potency of XRCC3 in the formation of chemotherapy resistance. Our results indicated that XRCC3 profoundly affects the formation of doxorubicin resistance and implicated that a complication exists between doxorubicin resistance and these repair pathways.
In this nuclear proteomic study, we determined numerous potential biological functions of the identified proteins in baseline resistance in MES-SA, MES-SA/Dx-2M, and MES-SA/Dx-8M cells by using a Swiss-Prot search and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Our findings are useful for systematic study of the mechanisms of dox-orubicin resistance in uterine cancer, especially study focused on nuclear networks. Table 1 illustrates a statistical comparison of the differentially expressed nuclear proteins for doxorubicininduced baseline resistance. Nuclear proteins known to regulate gene expression are downregulated in resistance cells. By contrast, nuclear proteins known to modulate protein folding and redox-regulation are upregulated in resistance cells implying that doxorubicin-resistant cells have low ability in transcriptional control but considerable ability in maintaining nuclear protein conformation and folding as well as in maintaining the redox balance in the nucleus.
A protein species hypothesis was proposed to be the minimum unit of the proteome and believe the formation of different forms of protein (such as posttranslational modifications), each of which has a specific function and chemical structure. The original synthesis product of translation is a prototype protein species, the initial protein species. This initial protein species is probably further biochemically processed, modified, or proteolytically secreted out of the cell or is transported to intracellular organelles and spliced or degraded. Each of these covalent modifications of a protein results in a new protein species (Jungblut et al., 2008; Schluter et al., 2009) . In this study, some of identified proteins including far upstream element-binding protein 2, heat shock protein beta-1, heterogeneous nuclear ribonucleoprotein K, heterogeneous nuclear ribonucleoprotein L, and non-POU domain-containing octamer-binding protein have been identified at multiple spots (Table 1 and Fig. 3 ), implying that these proteins undergo various processes and modifications and form new protein species against initial translational products.
In summary, our nuclear proteomic approaches allowed us to identify numerous nuclear proteins, including XRCC3 involved in various drug-resistance-forming mechanisms. Our results provide useful diagnostic markers and therapeutic candidates for the treatment of doxorubicin-resistant uterine cancer.
